1. Home
  2. CGON vs VSTS Comparison

CGON vs VSTS Comparison

Compare CGON & VSTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • VSTS
  • Stock Information
  • Founded
  • CGON 2010
  • VSTS 1936
  • Country
  • CGON United States
  • VSTS United States
  • Employees
  • CGON N/A
  • VSTS N/A
  • Industry
  • CGON
  • VSTS
  • Sector
  • CGON
  • VSTS
  • Exchange
  • CGON NYSE
  • VSTS Nasdaq
  • Market Cap
  • CGON 2.4B
  • VSTS 2.2B
  • IPO Year
  • CGON 2024
  • VSTS N/A
  • Fundamental
  • Price
  • CGON $28.45
  • VSTS $16.07
  • Analyst Decision
  • CGON Strong Buy
  • VSTS Hold
  • Analyst Count
  • CGON 8
  • VSTS 6
  • Target Price
  • CGON $63.88
  • VSTS $15.73
  • AVG Volume (30 Days)
  • CGON 819.4K
  • VSTS 2.1M
  • Earning Date
  • CGON 02-02-2025
  • VSTS 02-05-2025
  • Dividend Yield
  • CGON N/A
  • VSTS 0.89%
  • EPS Growth
  • CGON N/A
  • VSTS N/A
  • EPS
  • CGON N/A
  • VSTS 0.16
  • Revenue
  • CGON $684,000.00
  • VSTS $2,805,820,000.00
  • Revenue This Year
  • CGON $165.75
  • VSTS $3.18
  • Revenue Next Year
  • CGON $47.04
  • VSTS $3.01
  • P/E Ratio
  • CGON N/A
  • VSTS $101.03
  • Revenue Growth
  • CGON 258.12
  • VSTS N/A
  • 52 Week Low
  • CGON $25.77
  • VSTS $8.92
  • 52 Week High
  • CGON $50.23
  • VSTS $22.37
  • Technical
  • Relative Strength Index (RSI)
  • CGON 31.50
  • VSTS 58.99
  • Support Level
  • CGON $27.58
  • VSTS $15.95
  • Resistance Level
  • CGON $36.73
  • VSTS $16.46
  • Average True Range (ATR)
  • CGON 2.01
  • VSTS 0.49
  • MACD
  • CGON -0.52
  • VSTS -0.06
  • Stochastic Oscillator
  • CGON 9.51
  • VSTS 18.78

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

Share on Social Networks: